Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Protagonist Therapeutics Inc.

www.protagonist-inc.com

Latest From Protagonist Therapeutics Inc.

Deal Watch: Gilead Moves Into Kidney Disease Via Goldfinch Collaboration

Goldfinch’s Kidney Genome Atlas may yield novel therapies for diabetic kidney disease and orphan renal indications, with Gilead holding option rights. Spectrum licenses IP from ImmunGene that could safely harness the potential of interferon therapy in cancer.

Deals Business Strategies

Landos Leverages Advanced Computing For Autoimmune Disease Drug Development

Emerging Company Profile: Start-up Landos is raising money through a Series B financing to fund Phase II development of its lead oral, gut-restricted compound and described its plans in a video interview at the Biotech Showcase in San Francisco in January. 

 

 

StartUps and SMEs Companies

Finance Watch: Vaccinex, Aridis Launch August's First US IPOs As The Summer Simmer Slows

The summer slowdown finally seems to have hit the US biopharma IPO market; after a hot July with nine offerings, there were just two during the first half of August. Also, Zogenix leads recent follow-ons with a $312m offering; venture capital planted in UK biotechs – Orchard and Blueberry.

Financing Business Strategies

Pipeline Watch: Phase III Progress With BL-8040, Recorlev And Estelle

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Gastrointestinal
  • Inflammation
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Protagonist Therapeutics Inc.
  • Senior Management
  • Dinesh V Patel, PhD, Pres. & CEO
    Don Kalkofen, CFO
    David Y Liu, PhD, CSO & Head, R&D
    Samuel Saks, MD, CMO
  • Contact Info
  • Protagonist Therapeutics Inc.
    Phone: (510) 474-0170
    7707 Gateway Blvd., Ste. 140
    Newark, CA 94560-1160
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register